Orthofix Medical (OFIX) Expected to Announce Earnings on Tuesday

Orthofix Medical (NASDAQ:OFIX) is expected to issue its quarterly earnings data before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of $0.06 per share and revenue of $212.72 million for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Orthofix Medical Stock Down 0.8 %

NASDAQ OFIX opened at $17.95 on Friday. The company has a market capitalization of $685.87 million, a price-to-earnings ratio of -5.73 and a beta of 1.10. The company has a current ratio of 2.39, a quick ratio of 1.11 and a debt-to-equity ratio of 0.25. Orthofix Medical has a 1-year low of $12.08 and a 1-year high of $20.73. The stock’s 50 day moving average is $17.94 and its two-hundred day moving average is $17.33.

Analyst Upgrades and Downgrades

Several analysts have commented on OFIX shares. StockNews.com upgraded shares of Orthofix Medical from a “hold” rating to a “buy” rating in a research report on Friday, January 31st. Canaccord Genuity Group assumed coverage on shares of Orthofix Medical in a research note on Wednesday, January 22nd. They issued a “buy” rating and a $24.00 target price for the company. Stifel Nicolaus upgraded shares of Orthofix Medical from a “hold” rating to a “buy” rating and increased their price objective for the stock from $18.00 to $24.00 in a research note on Friday, November 8th. Finally, Roth Mkm reiterated a “buy” rating and issued a $22.00 target price (up from $20.00) on shares of Orthofix Medical in a research note on Friday, November 8th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $23.33.

Insider Transactions at Orthofix Medical

In other news, CFO Julie Andrews sold 4,655 shares of the business’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $17.89, for a total transaction of $83,277.95. Following the completion of the sale, the chief financial officer now directly owns 28,312 shares of the company’s stock, valued at $506,501.68. The trade was a 14.12 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Massimo Calafiore sold 10,078 shares of the company’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $16.83, for a total transaction of $169,612.74. Following the completion of the sale, the chief executive officer now directly owns 133,354 shares of the company’s stock, valued at $2,244,347.82. The trade was a 7.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 25,442 shares of company stock worth $436,883. Company insiders own 2.60% of the company’s stock.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.